论文部分内容阅读
Objective:To evaluate changes in chest X-rays,pulmonary function tests (PFTs) and quality of life in female breast cancer patients who had been treated with four cycles of neoadjuvant chemotherapy consisting of a regimen of cyclophosphamide,epirubicin and 5-fluorouracil (CEF regimen),and to determine the correlation between pulmonary function parameters and declined quality of life.Methods:Twenty-nine eligible female patients diagnosed with breast cancer at the first visit who were 20-60 years old,were classified as the American Society of Anesthesiologists (ASA) Ⅰ-Ⅱ and patients whose body mass index (BMI) <30 kg/m2 were recruited and subjected to chest X-ray examinations,PFTs and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)questionnaire before and after receiving 4 cycles of the CEF regimen.Results:In this study,chest X-rays showed no abnormal changes after chemotherapy,but significant decreases in carbon monoxide diffusing capacity (DLCO) and percentage of the DLCO predicted value (DLCO%) (P<0.001).A significant increase in maximal ventilatory volume (MVV) (P=0.004) was observed,and most patients experienced dyspnea (P=0.031) and fatigue (P<0.001).However,there was no significant correlation between the changes in these PFTs parameters and the results of the EORTC QLQ-C30 (P>0.05).Conclusions:Neoadjuvant chemotherapy can reduce lung diffusion function and quality of life in females with breast cancer.